WARRENDALE, Pennsylvania, November 20 /PRNewswire/ --
- Design of Spectris Solaris(R) EP Mobile Solution MR Injection System Sets Space-Saving Standard
With the introduction of the Spectris Solaris(R) EP Mobile MR Injection System today, MEDRAD once again addresses the challenges clinicians face in a mobile magnetic resonance (MR) imaging trailer with market-leading injector technology suited for small spaces.
The new Spectris Solaris EP Mobile is specifically tailored for the mobile MR trailer environment and combines proven MEDRAD reliability and performance with space-saving efficiency. The Spectris Solaris EP Mobile sets the standard for space-savings with an off-the-floor design, compact storage against the trailer wall, new AC power solution, and equal access to either arm of the patient.
"We've modified the MR injection system to mount the power unit and injector head advantageously on the trailer wall and free up valuable floor space," said Joe Havrilla, senior vice-president, MR Business Unit for MEDRAD. "The Mobile Solution gives clinicians the same proven reliability and performance of our market-leading injection system suited perfectly for the tight quarters of mobile MR."
The Spectris Solaris EP Mobile Solution can be ordered through MEDRAD representatives throughout the U.S. and Europe.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were US$478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Dan Dieter, MEDRAD Marketing Services, +1-724-940-6949, email@example.com, or Mick Trainor, MEDRAD MR, +1-412-767-2400 ext. 3784, firstname.lastname@example.org, both of MEDRAD ; Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO, AP Archive: http://photoarchive.ap.org, PRN Photo Desk, email@example.com